Loading...

Financial Summary


Precipio Inc.

Precipio Inc. (PRPO)

Healthcare
Buy
A+
Market Info
Financial Info
Financial Modelling
Symbol PRPO
Price 2.75$
Beta 1.53
Volume Avrg. 1.68M
Market Cap 0.00B
Shares (2018) 1,441.11K
Last Div 0
Dividend Yield -
DCF Unlevered -168.12 Strong Sell
DCF Levered -101.28 Strong Sell
ROE -256.31% Strong Sell
ROA 136.75% Strong Buy
Operating Margin -485.75% Strong Sell
Debt / Equity 83.37% Buy
P/E - Neutral
P/B 0.54 Buy

Income Statement

Download PRPO income statement Download PRPO income statement
Year 2009201020112012201320142015201620172018
Revenue 22.0220.0531.9731.4827.541.241.932.691.722.86
Cost of Revenue 10.4210.2813.5318.3516.792.171.941.941.432.64
Gross Profit 11.619.7618.4413.1310.75-0.94-0.010.750.290.23
R&D Expenses 3.182.312.222.493.212.251.85---
Sales, General and Administrative Expense 10.3210.9319.1520.1423.307.387.052.466.499.45
Operating Expenses 13.5013.3821.4122.6426.519.638.912.4615.8014.14
Operating Income -1.90-3.61-2.97-9.50-15.76-10.57-8.92-1.71-15.51-13.91
Interest Expense -0.010.000.960.890.640.670.720.522.320.27
Earnings before Tax -1.88-2.98-9.74-8.18-16.04-13.94-32.95-2.23-20.69-15.97
Income Tax Expense 0.040.150.040.15-0.05-----0.28
Net Income -1.92-3.13-9.78-8.33-15.99-13.94-32.95-2.23-20.69-15.69
Net Income - Non-Controlling int ----------
Net Income - Discounted ops ----------
Net Income Com -1.92-3.13-10.79-8.99-16.71-15.09-34.28-4.08-33.21-19.92
Preferred Dividends --1.010.660.731.141.321.8512.524.22
Earnings Per Share Basic -216.00-324.00-1,179.00-697.50-1,035.00-904.50-1,251.00-141.60-107.40-13.80
Earnings Per Share Diluted -216.00-324.00-1,179.00-697.50-1,035.00-904.50-1,251.00-141.60-107.40-13.80
Weighted Average Shares Outstanding 0.010.010.010.010.020.020.030.030.311.44
Weighted Average Shares Outstanding (Diluted) 0.010.010.010.010.020.020.030.030.311.44
Dividend per Share ----------
Gross Margin 0.530.490.580.420.39-0.75-0.010.280.170.08
EBITDA Margin -0.05-0.11-0.21-0.16-0.46-10.25-16.45-0.59-10.23-5.04
EBIT Margin -0.09-0.15-0.27-0.23-0.56-10.71-16.71-0.63-10.66-5.48
Profit Margin -0.09-0.16-0.34-0.28-0.61-12.17-17.77-1.52-19.27-6.95
Free Cash Flow margin 0.00-0.00-0.00-0.00-0.00-0.00-0.00-0.00-0.00-0.00
EBITDA -1.04-2.27-6.68-5.01-12.65-12.71-31.74-1.60-17.63-14.44
EBIT -1.89-2.98-8.78-7.29-15.40-13.28-32.23-1.71-18.37-15.70
Consolidated Income -1.92-3.13-9.78-8.33-15.99-13.94-32.95-2.23-20.69-15.69
Earnings Before Tax Margin -0.09-0.15-0.30-0.26-0.58-11.24-17.08-0.83-12.01-5.58
Net Profit Margin -0.09-0.16-0.31-0.26-0.58-11.24-17.08-0.83-12.01-5.48

Balance Sheet Statement

Download PRPO income statement Download PRPO income statement
Year 2009201020112012201320142015201620172018
Cash and cash equivalents 5.643.454.954.501.631.610.440.050.420.38
Short-term investments ----------
Cash and short-term investments 5.643.454.954.501.631.610.440.050.420.38
Receivables 4.527.607.578.085.310.470.260.390.730.69
Inventories 3.553.343.865.093.96-0.050.100.160.20
Property, Plant & Equipment Net 0.971.601.862.192.000.480.260.280.350.50
Goodwill and Intangible Assets 0.3815.2414.4117.6816.110.751.17-25.1419.29
Long-term investments ----------
Tax assets ----------
Total non-current assets 0.2413.826.193.2510.2111.470.664.294.201.72
Total current assets 1.5516.9916.3620.0718.441.441.530.2925.5219.81
Total assets 16.0032.0333.5638.7930.2830.014.820.8427.2621.61
Payables 1.011.362.612.052.863.903.781.085.105.17
Short-term debt -1.166.796.170.240.467.601.140.644.70
Total current liabilities 4.108.2516.3315.278.6311.9916.983.0110.0413.77
Long-term debt -8.644.94-6.327.38-4.292.940.41
Total debt -9.8011.726.176.567.847.605.433.585.11
Deferred revenue --1.381.171.090.300.220.090.070.05
Tax Liabilities ----------
Deposit Liabilities ----------
Total non-current liabilities 0.2413.826.193.2510.2111.470.664.294.201.72
Total liabilities 4.3422.0722.5118.5218.8323.4517.647.3014.2315.48
Other comprehensive income 1.651.590.340.430.390.340.01---
Retained earnings (deficit) -130.18-133.32-142.80-151.79-168.50-183.59-213.41-10.85-31.54-47.70
Total shareholders equity 11.668.5011.0520.2711.456.55-12.82-6.4613.036.12
Investments ----------
Net Debt -5.646.346.781.674.936.237.155.383.164.72
Other Assets 0.740.640.821.050.9426.492.520.010.430.53
Other Liabilities 3.095.736.937.045.527.635.600.794.303.90

Cash Flow Statement

Download PRPO income statement Download PRPO income statement
Year 2009201020112012201320142015201620172018
Depreciation & Amortization 0.850.712.102.282.750.570.490.110.741.26
Stock-based compensation 0.20-0.011.010.730.460.940.610.010.050.53
Operating Cash Flow 1.27-1.720.22-10.20-8.47-13.70-12.38-0.96-6.69-6.75
Capital Expenditure -0.35-0.19-0.23-0.88-0.60-0.13-0.20--0.14-0.10
Acquisitions and disposals --6.00--3.55-0.85---0.10-
Investment purchases and sales ----------
Investing Cash Flow ----------
Insurance (repayment) of debt ----------
Insurance (buybacks) of shares ----------
Dividend payments ----------
Financing Cash Flow -5.761.7314.607.3710.078.990.787.106.81
Effect of forex changes on cash -0.02-0.010.050.03-0.00-0.010.43---
Net cash flow / Change in cash 0.87-2.191.49-0.45-2.87-0.02-1.17-0.180.37-0.04
Free Cash Flow 0.92-1.91-0.01-11.09-9.08-13.83-12.58-0.96-6.83-6.85
Net Cash/Marketcap 0.000.000.000.000.000.000.000.00-0.00-0.00

Retained Earning Schedule

Year 2009201020112012201320142015201620172018
Retained Earnings (Previous Year) --130-133-143-152-169-184-213-11-32
Net Income -2-3-10-8-16-14-33-2-21-16
Stock Dividends -128-0-1-1-13205--0
Divident Paid ----------
Retained Earnings -130-133-143-152-169-184-213-11-32-48
Year 2009201020112012201320142015201620172018
Gross PPE -122220000
Annual Depreciation 11010-1-0000
Capital Expenditure -0-0-0-1-1-0-0--0-0
Net PPE 1222200000

Intangible and Goodwill Schedule

Year 2009201020112012201320142015201620172018
Intangible and Goodwill (Previous Year) -01514181611-25
New Purchases ----------
Intangible and Goodwill 01514181611-2519
Precipio Inc.

Precipio Inc. (PRPO)

2.75
0 (0.00%)

About


Ilan Danieli
Healthcare
Medical Diagnostics & Research
NASDAQ Capital Market

Precipio Inc is a diagnostics company, which has built a platform designed to eradicate the problem of misdiagnosis by harnessing the expertise and technology developed within academic institutions and delivering diagnostic information to physicians.